For Employers | On-site Med

Complete Testing Solutions for Employers

On-Site Medical’s Employee COVID-19 Compliance Testing program provides information you need to help protect your employees in the face of new variants.

Our simple-to-execute, fully customizable solutions are focused on keeping your workforce safe and healthy on the job.

And with our convenient and cost-effective SARS-CoV-2 testing options, implementation has never been easier. On-Site Medical Services provides molecular (PCR), rapid antigen, and antibody blood tests to meet your needs.

Accurate, reliable testing options:

Molecular (PCR) current infection swab testsdetect or confirm the presence of the virus with convenient self-collection at home, at work, or at a Quest location
Rapid antigen tests provide results in just 15 to 30 minutes followed by a Quest PCR test to confirm a positive result
IgG antibody blood tests detect antibodies that show if an individual may have had a prior or recent infection

On-Site Medical Services will support continued testing efforts as long as COVID-19 and its variants present a risk to your business.

On-Site Medical Services combines the efficiency of a dedicated testing service with the intimacy of a family practice

Scalable to meet your ever-changing needs:

Flexible

Our size enables us to collect and analyze COVID-19 testing efforts expeditiously.

Stay Up and Running

Monitor for symptoms, provide ongoing testing, and isolate any active cases on-site.

Ongoing Testing

Re-screen employees at regular intervals or after they return from time off.

Flexible to give you options:

At home

Molecular current infection swab tests are offered via self-collection kits with results sent to our Wellbility App.

At work

Consider ongoing molecular swab tests, rapid antigen tests, IgG antibody blood tests, and temperature checks for all staff.

At On-Site

IgG antibody blood tests are available at one of our dedicated testing facilities.

Data and reporting solutions:

Onboarding

Digital onboarding process with intuitive steps makes it simple for employers to launch the program and for staff to register, make appointments, and check in.

Patient Results

Employees are alerted via email when test results are ready. The easy-to-understand results can be printed or shared.

Confidential Reporting

Employer administrators can get daily email reports to review and verify employee participation status and results, while also adhering to privacy laws.

Intervention at critical touchpoints:

Surveillance

Deploy molecular (PCR) swab tests, rapid antigen tests, or IgG antibody blood tests to track overall positivity among employees.

Diagnostics

Check symptomatic employees with molecular current infection swab testing or rapid antigen testing.

Outbreak

Manage infection outbreaks with self-collection molecular tests and contactless drop-off and pickup.

Employees should always discuss their signs and symptoms, as well as any positive test results, with their physicians.

Important information about COVID-19 antibody testing

The test is designed to detect antibodies to SARS-CoV-2, the virus that causes COVID-19. Antibodies are proteins that the body produces in response to infections. The antibodies can be produced even if a person has few or no symptoms during the infection.

It generally takes some time after infection for antibodies to be produced and become detectable in blood (sometimes up to 3 weeks). It is important to remember that we do not yet know whether having antibodies to SARS-CoV-2 will prevent against getting the infection again or if you are totally free of the virus. Antibodies are generally detectable in the blood for a period of time after a person has recovered from the infection and after the virus that caused the infection is no longer detectable by laboratory methods.

Sometimes the antibodies developed in response to an infection protect us from getting that same infection again. But, it is important to know that we do not yet know whether this is true for COVID-19. Even if you have recovered and have antibodies, there is a chance that you still have the virus and you can infect others, so it is still critical to keep taking measures to avoid getting infected again and/or spreading infection.

The antibody test is not meant for detecting a current infection. The swab test (sometimes also known as a molecular, RNA, or PCR test) should be used to test for a current infection.

A negative antibody test result means that antibodies were not detected in your blood sample. This can have several possible meanings. It could mean that:

You have not been infected with SARS-CoV-2, or
You have been infected with SARS-CoV-2, but your antibodies have not reached a sufficient level for the test to be able to detect them, or
You have been infected with SARS-CoV-2, but there has not been enough time for antibodies to develop (it can take up to 1 to 3 weeks to develop antibodies after someone is infected, sometimes longer).

A positive antibody test result means that antibodies were detected in your blood sample. This can have a couple of possible meanings. It could mean that:

You have been infected with SARS-CoV-2 at some point in the past, or
Uncommonly, you may have developed antibodies from an earlier infection with a different virus related to SARS-CoV-2 and the laboratory test cannot distinguish between these other virus antibodies and those antibodies generated in response to SARS-CoV-2.

COVID-19 testing statements

The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
All tests have been authorized by FDA under EUAs for use by authorized laboratories;
The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses, pathogens; and,
All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.